An FDA advisory panel recommended that compounding pharmacies be allowed to manufacture epitalon while narrowly voting against allowing pharmacies to make emideltide. The votes followed a previous advisory panel recommendation to permit compounding for four other peptides, moving the policy discussion closer to broader access for unapproved compounds. The decision comes as health secretary Robert F. Kennedy Jr. advances an initiative to increase availability of unapproved peptide products. The panel’s split recommendation highlights how the agency’s expert committee is scrutinizing quality, risk, and evidence standards even within the same class of products. For pharmacies and clinicians, the near-unanimous allowance for one peptide and rejection for the other sets up a staggered implementation path—potentially affecting patient supply and future compounding requests.